製劑開發外包市場 - 2018-2028 年全球行業規模、佔有率、趨勢、機會和預測，按服務、製劑、治療領域、地區和競爭細分

預計製劑開發外包市場在預測期內將出現令人印象深刻的成長。這可以歸因於對新藥的需求不斷成長、專利到期以及對開發水溶性差的化合物以提高生物利用度的關注。此外，克服與開發相關的風險的需求不斷成長，以及對學名藥和生物學名藥的需求不斷成長，預計將在預測期內創造利潤豐厚的成長。同樣，製藥組織越來越注重研發活動，以保持競爭力和靈活性，這是多年來推動市場成長的主要因素。 2021 年 6 月，Taylor France 發表了一篇關於使用 3D 列印來配製和開發個性化藥物的論文。 2022年3月，美國國際開發署（USAID）宣佈為藥物開發提供1.5億美元資金。此類舉措可能有利於市場的成長。

節約成本

成本節約是全球製劑開發外包市場成長的關鍵驅動力之一。製藥公司面臨著降低成本和提高效率的壓力，外包製劑開發可以通過多種方式幫助他們實現這些目標。首先，外包製劑開發使製藥公司能夠避免與建設和維護設施和設備相關的資本支出，以及持續的人員配備和培訓成本。

專注於核心能力。

核心能力是影響全球製劑開發外包市場成長的另一個關鍵因素。製藥公司越來越認知到專注於核心競爭力以保持競爭力和創新的重要性。外包配方開發可以通過多種方式幫助公司實現這一目標。首先，外包製劑開發使製藥公司能夠專注於其核心競爭力，例如藥物發現、行銷和銷售。通過與專門從事配方開發的 CDMO（契約開發和製造組織）合作，公司可以騰出資源投資於他們具有競爭優勢的領域。這可以幫助他們更快、更高效地開發新藥，並更快地將其推向市場。其次，外包製劑開發使製藥公司能夠獲得其內部可能沒有的專業知識和設施。許多 CDMO 專注於配方開發的特定領域，例如生物製劑、無菌產品或受控物質。

通過與這些專業合作夥伴合作，公司可以獲得更有效地開發藥物配方所需的專業知識和基礎設施。第三，外包製劑開發可以幫助製藥公司降低風險並提高靈活性。通過與多個 CDMO 合作，公司可以分散風險並確保他們能夠獲得開發藥物配方所需的專業知識和基礎設施，無論其具體要求如何。

藥物開發的複雜性增加

藥物開發是全球製劑開發外包市場成長的重要驅動力。製藥行業面臨著開發新藥和創新藥物以滿足未滿足的醫療需求的持續壓力，外包製劑開發可以通過多種方式幫助公司加快藥物開發進程。外包配方開發可以幫助製藥公司縮短上市時間。通過與專門從事製劑開發的 CDMO（契約開發和製造組織）合作，公司可以獲得更快速、更高效地開發藥物製劑所需的專業知識和基礎設施。這可以幫助他們更快地將藥物推向市場並更快地佔領市場佔有率。此外，外包製劑開發可以幫助製藥公司獲得專業知識和設施。

許多 CDMO 專注於配方開發的特定領域，例如生物製劑、無菌產品或受控物質。通過與這些專業合作夥伴合作，公司可以獲得更有效地開發藥物配方所需的專業知識和基礎設施。此外，外包製劑開發可以幫助製藥公司降低開發成本。通過利用 CDMO 的專業知識和基礎設施，公司可以從規模經濟中受益並降低總體開發成本。這可以幫助他們更有效地分配資源並投資於其他業務領域，例如藥物發現、行銷和銷售。

快速發展的監管環境

監管環境是影響全球製劑開發外包市場成長的關鍵因素。製藥行業受到嚴格的監管要求，外包製劑開發可以幫助公司更有效地滿足這些要求。首先，外包製劑開發可以幫助製藥公司更有效地遵守監管要求。專門從事配方開發的 CDMO（契約開發和製造組織）通常在與監管機構合作方面經驗豐富，可以幫助公司應對複雜的監管環境。這可以幫助公司避免延誤和代價高昂的監管錯誤，這些錯誤可能會減慢藥物開發過程並增加成本。其次，外包製劑開發可以幫助製藥公司獲得與監管合規性相關的專業知識。許多 CDMO 擁有內部監管專家，他們可以提供監管合規指導，以及開發滿足監管要求的藥物配方所需的專業知識。第三，製劑開發外包可以幫助製藥公司遵守不斷變化的監管要求。隨著法規的發展，CDMO 可以幫助公司了解最新情況並相應地調整其藥物開發流程，從而降低不合規和相關處罰的風險。

對生物製劑和其他複雜製劑的需求不斷成長

生物製劑和其他複雜製劑是全球製劑開發外包市場成長的重要驅動力。生物製劑和其他複雜製劑需要內部可能無法提供的專業知識和專業知識。專門從事生物製品和其他複雜配方的 CDMO（契約開發和製造組織）擁有必要的知識和專業知識來更有效地開發和製造這些產品。通過與這些專業合作夥伴合作，製藥公司可以獲得更高效、更有效地開發生物製劑和其他複雜製劑所需的專業知識和基礎設施。此外，生物製劑和其他複雜製劑通常需要內部可能不具備的專門基礎設施。專門從事生物製劑和其他複雜製劑的 CDMO 已投資開發和製造這些產品所需的基礎設施，包括專用設備和設施。通過與這些專業合作夥伴合作，製藥公司可以獲得更高效、更具成本效益地開發生物製劑和其他複雜製劑所需的基礎設施。此外，外包生物製劑和其他複雜製劑的開發可以幫助製藥公司降低風險。這些制定通常涉及高度的複雜性和風險，外包開發過程可以幫助公司分散風險並確保他們能夠獲得必要的專業知識和基礎設施。

近期發展

• Catalent 於 2020 年推出了新的噴霧乾燥套件，其中包括具有整合研磨和顆粒工程功能的 GMP 噴霧乾燥器。這個新套件使康泰倫特能夠提供更廣泛的藥物開發服務，包括噴霧乾燥、微粉化和製劑開發。
• Thermo Fisher Scientific 於 2020 年在新加坡推出了新的 CDMO 設施，其中包括配方開發、工藝開發和臨床試驗製造等一系列功能。該設施旨在支持亞太地區對 CDMO 服務不斷成長的需求。
• Lonza 於 2019 年在瑞士推出了新的無菌藥品灌裝和加工設施，其中包括無菌灌裝、凍乾和最終滅菌功能。新工廠擴大了 Lonza 在無菌藥品製造領域的能力，並使該公司能夠為客戶提供更廣泛的服務。

可用的客製化：

根據給定的市場數據，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自定義選項：

公司資訊

• 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 考慮學習的年份
  • 主要市場細分

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要行業合作夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量和驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球製劑開發外包市場展望

• 市場規模及預測
  • 按價值
• 市場佔有率及預測
  • 按服務分類（預製劑、製劑開發）
  • 按劑型（口服、注射、外用、其他）
  • 按治療領域（腫瘤科、傳染病科、神經科、血液科、呼吸科、心血管科、皮膚科、其他）
  • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
  • 按公司分類 (2022)
• 市場地圖
  • 按服務
  • 按配方分類
  • 按治療領域
  • 按地區

第 6 章：北美製劑開發外包市場展望

• 市場規模及預測
  • 按價值
• 市場佔有率及預測
  • 按服務分類（預製劑、製劑開發）
  • 按劑型（口服、注射、外用、其他）
  • 按治療領域（腫瘤科、傳染病科、神經科、血液科、呼吸科、心血管科、皮膚科、其他）
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲製劑開發外包市場展望

• 市場規模及預測
  • 按價值
• 市場佔有率及預測
  • 按服務分類（預製劑、製劑開發）
  • 按劑型（口服、注射、外用、其他）
  • 按治療領域（腫瘤科、傳染病科、神經科、血液科、呼吸科、心血管科、皮膚科、其他）
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太製劑開發外包市場展望

• 市場規模及預測
  • 按價值
• 市場佔有率及預測
  • 按服務分類（預製劑、製劑開發）
  • 按劑型（口服、注射、外用、其他）
  • 按治療領域（腫瘤科、傳染病科、神經科、血液科、呼吸科、心血管科、皮膚科、其他）
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳大利亞

第 9 章：南美製劑開發外包市場展望

• 市場規模及預測
  • 按價值
• 市場佔有率及預測
  • 按服務分類（預製劑、製劑開發）
  • 按劑型（口服、注射、外用、其他）
  • 按治療領域（腫瘤科、傳染病科、神經科、血液科、呼吸科、心血管科、皮膚科、其他）
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲製劑開發外包市場展望

• 市場規模及預測
  • 按價值
• 市場佔有率及預測
  • 按服務分類（預製劑、製劑開發）
  • 按劑型（口服、注射、外用、其他）
  • 按治療領域（腫瘤科、傳染病科、神經科、血液科、呼吸科、心血管科、皮膚科、其他）
  • 按國家/地區
• MEA：國家分析
  • 南非製劑開發外包
  • 沙烏地阿拉伯製劑開發外包
  • 阿拉伯聯合大公國配方開發外包

第 11 章：市場動態

• 司機
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：全球製劑開發外包市場：SWOT 分析

第 14 章：波特的五力分析

• 行業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第15章：競爭格局

• 商業概覽
• 產品供應
• 最近的發展
• 財務（據報導）
• 主要人員
• SWOT分析
  • Charles River Laboratories.
  • Aizant Drug Research Solutions Private Limited.
  • Catalent Inc.
  • Laboratory Corporation of America Holdings.
  • Syngene International Ltd.
  • Irisys LLC.
  • Intertek Group PLC.
  • Piramal Pharma Solutions.
  • Qiotient Sciences Ltd.
  • Patheon Inc.
  • Emergent BioSolutions Inc
  • Lonza Group AG

第 16 章：戰略建議

Formulation Development Outsourcing Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing demand for new drugs, patent expirations, and a focus on developing poorly water-soluble compounds to improve bioavailability. Also, the growing demand for overcoming the risk associated with development and growing demand for generics and biosimilar drugs is expected to create lucrative growth during the forecast period. Similarly, pharmaceutical organizations are increasingly focusing on their R&D activities to stay competitive and flexible, which is a major factor fueling the growth of the market over the years. In June 2021, Taylor France published a paper regarding the use of 3D printing for the formulation and development of personalized medicines. In March 2022, the United States Agency for International Development (USAID) announced USD 150 million in funding for drug development. Such initiatives are likely to benefit the market's growth.

Cost savings

Cost savings are one of the key drivers of the growth of the Global Formulation Development Outsourcing Market. Pharmaceutical companies are under pressure to reduce costs and improve efficiency, and outsourcing formulation development can help them achieve these goals in several ways. First, outsourcing formulation development allows pharmaceutical companies to avoid the capital expenditures associated with building and maintaining facilities and equipment, as well as the ongoing costs of staffing and training employees.

Instead, companies can leverage the expertise and infrastructure of CDMOs (Contract Development and Manufacturing Organizations) to develop their drug formulations. Second, outsourcing formulation development can help pharmaceutical companies to reduce their overall development costs. By working with CDMOs that specialize in formulation development, companies can benefit from economies of scale, as well as the expertise of specialized professionals. This can result in reduced development costs and faster time-to-market.

Third, outsourcing formulation development allows pharmaceutical companies to allocate their resources more effectively. By focusing on their core competencies, such as drug discovery, marketing, and sales, companies can free up resources to invest in other areas of their business. This can help companies to improve their competitive position and increase their profitability.

Focus on core competencies.

Core competencies are another key factor influencing the growth of the Global Formulation Development Outsourcing Market. Pharmaceutical companies are increasingly recognizing the importance of focusing on their core competencies to remain competitive and innovative. Outsourcing formulation development can help companies achieve this goal in several ways. First, outsourcing formulation development allows pharmaceutical companies to focus on their core competencies, such as drug discovery, marketing, and sales. By working with CDMOs (Contract Development and Manufacturing Organizations) that specialize in formulation development, companies can free up resources to invest in areas where they have a competitive advantage. This can help them to develop new drugs more quickly and efficiently and to bring them to market faster. Second, outsourcing formulation development allows pharmaceutical companies to access specialized expertise and facilities that they may not have in-house. Many CDMOs specialize in specific areas of formulation development, such as biologics, sterile products, or controlled substances.

By working with these specialized partners, companies can access the expertise and infrastructure needed to develop their drug formulations more effectively. Third, outsourcing formulation development can help pharmaceutical companies to reduce their risk and increase their flexibility. By working with multiple CDMOs, companies can spread their risk and ensure that they have access to the expertise and infrastructure needed to develop their drug formulations, regardless of their specific requirements.

Increased complexity of drug development

Drug development is a significant driver of the growth of the Global Formulation Development Outsourcing Market. The pharmaceutical industry is under constant pressure to develop new and innovative drugs to address unmet medical needs, and outsourcing formulation development can help companies accelerate the drug development process in several ways. Outsourcing formulation development can help pharmaceutical companies to reduce their time-to-market. By working with CDMOs (Contract Development and Manufacturing Organizations) that specialize in formulation development, companies can access the expertise and infrastructure needed to develop their drug formulations more quickly and efficiently. This can help them to bring their drugs to market faster and to capture market share more quickly. Also, outsourcing formulation development can help pharmaceutical companies to access specialized expertise and facilities.

Many CDMOs specialize in specific areas of formulation development, such as biologics, sterile products, or controlled substances. By working with these specialized partners, companies can access the expertise and infrastructure needed to develop their drug formulations more effectively. Additionally, outsourcing formulation development can help pharmaceutical companies to reduce their development costs. By leveraging the expertise and infrastructure of CDMOs, companies can benefit from economies of scale and reduce their overall development costs. This can help them to allocate their resources more effectively and invest in other areas of their business, such as drug discovery, marketing, and sales.

The rapidly evolving regulatory environment

The regulatory environment is a crucial factor that influences the growth of the Global Formulation Development Outsourcing Market. The pharmaceutical industry is subject to strict regulatory requirements, and outsourcing formulation development can help companies navigate these requirements more effectively. First, outsourcing formulation development can help pharmaceutical companies to comply with regulatory requirements more efficiently. CDMOs (Contract Development and Manufacturing Organizations) that specialize in formulation development are often experienced in working with regulatory bodies and can help companies navigate the complex regulatory landscape. This can help companies to avoid delays and costly regulatory mistakes, which can slow down the drug development process and increase costs. Second, outsourcing formulation development can help pharmaceutical companies to access specialized expertise related to regulatory compliance. Many CDMOs have in-house regulatory experts who can provide guidance on regulatory compliance, as well as the expertise needed to develop drug formulations that meet regulatory requirements. Third, the outsourcing of formulation development can help pharmaceutical companies to maintain compliance with changing regulatory requirements. As regulations evolve, CDMOs can help companies to stay up-to-date and adapt their drug development processes accordingly, reducing the risk of non-compliance and associated penalties.

Growing demand for biologics and other complex formulations

Biologics and other complex formulations are significant drivers of the growth of the Global Formulation Development Outsourcing Market. Biologics and other complex formulations require specialized knowledge and expertise that may not be available in-house. CDMOs (Contract Development and Manufacturing Organizations) that specialize in biologics and other complex formulations have the necessary knowledge and expertise to develop and manufacture these products more effectively. By working with these specialized partners, pharmaceutical companies can access the expertise and infrastructure needed to develop their biologics and other complex formulations more efficiently and effectively. Besides, biologics and other complex formulations often require specialized infrastructure that may not be available in-house. CDMOs that specialize in biologics and other complex formulations have invested in the infrastructure needed to develop and manufacture these products, including specialized equipment and facilities. By working with these specialized partners, pharmaceutical companies can access the infrastructure needed to develop their biologics and other complex formulations more efficiently and cost-effectively. Moreover, outsourcing the development of biologics and other complex formulations can help pharmaceutical companies to reduce their risk. These formulations often involve a high degree of complexity and risk, and outsourcing the development process can help companies to spread their risk and ensure that they have access to the necessary expertise and infrastructure.

Recent Development

• Catalent launched a new spray drying suite in 2020, which includes a GMP spray dryer with integrated milling and particle engineering capabilities. This new suite allows Catalent to offer a wider range of drug development services, including spray drying, micronization, and formulation development.
• Thermo Fisher Scientific launched a new CDMO facility in Singapore in 2020, which includes a range of capabilities, including formulation development, process development, and clinical trial manufacturing. The facility is designed to support the growing demand for CDMO services in the Asia-Pacific region.
• Lonza launched a new sterile drug product fill and finish facility in Switzerland in 2019, which includes capabilities for aseptic filling, lyophilization, and terminal sterilization. The new facility expands Lonza's capabilities in the sterile drug product manufacturing space and allows the company to offer a wider range of services to its customers.

Market Segmentation

Global Formulation Development Outsourcing market can be segmented by service, formulation, therapeutic area, and by region. Based on the service, the market can be divided into preformulation and formulation development. Based on formulation, the market can be segmented into oral, injectable, topical, and others. Based on therapeutic areas, the market can be differentiated into oncology, infectious disease, neurology, hematology, respiratory, cardiovascular, dermatology, and others.

Market Players

Charles River Laboratories., Aizant Drug Research Solutions Private Limited., Catalent Inc., Laboratory Corporation of America Holdings., Syngene International Ltd., Irisys LLC., Intertek Group PLC., Piramal Pharma Solutions., Quotient Sciences Ltd., Patheon Inc., Emergent BioSolutions Inc, Lonza Group AG are some of the leading players operating in the Global Formulation Development Outsourcing Market.

Report Scope:

In this report, Global Formulation Development Outsourcing market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Formulation Development Outsourcing Market, By Product and Service:

• Consumables
• Instruments
• Services Instruments

Formulation Development Outsourcing Market, By Application:

• Drug Discovery & Development
• Clinical Diagnosis
• Others

Formulation Development Outsourcing Market, By End Use:

• Pharmaceuticals & Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations
• Others

Formulation Development Outsourcing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Formulation Development Outsourcing Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Formulation Development Outsourcing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Preformulation, Formulation Development)
  • 5.2.2. By Formulation (Oral, Injectable, Topical, Others)
  • 5.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others )
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2022)
• 5.3. Market Map
  • 5.3.1 By Service
  • 5.3.2 By Formulation
  • 5.3.3 By Therapeutic Area
  • 5.3.4 By Region

6. North America Formulation Development Outsourcing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service (Preformulation, Formulation Development)
  • 6.2.2. By Formulation (Oral, Injectable, Topical, Others)
  • 6.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Formulation Development Outsourcing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Formulation
      • 6.3.1.2.3. By Therapeutic Area
  • 6.3.2. Canada Formulation Development Outsourcing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Formulation
      • 6.3.2.2.3. By Therapeutic Area
  • 6.3.3. Mexico Formulation Development Outsourcing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Formulation
      • 6.3.3.2.3. By Therapeutic Area

7. Europe Formulation Development Outsourcing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service (Preformulation, Formulation Development)
  • 7.2.2. By Formulation (Oral, Injectable, Topical, Others)
  • 7.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Formulation Development Outsourcing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Formulation
      • 7.3.1.2.3. By Therapeutic Area
  • 7.3.2. Germany Formulation Development Outsourcing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Formulation
      • 7.3.2.2.3. By Therapeutic Area
  • 7.3.3. United Kingdom Formulation Development Outsourcing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Formulation
      • 7.3.3.2.3. By Therapeutic Area
  • 7.3.4. Italy Formulation Development Outsourcing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Formulation
      • 7.3.4.2.3. By Therapeutic Area
  • 7.3.5. Spain Formulation Development Outsourcing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Formulation
      • 7.3.5.2.3. By Therapeutic Area

8. Asia-Pacific Formulation Development Outsourcing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service (Preformulation, Formulation Development)
  • 8.2.2. By Formulation (Oral, Injectable, Topical, Others)
  • 8.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Formulation Development Outsourcing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Formulation
      • 8.3.1.2.3. By Therapeutic Area
  • 8.3.2. India Formulation Development Outsourcing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Formulation
      • 8.3.2.2.3. By Therapeutic Area
  • 8.3.3. Japan Formulation Development Outsourcing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Formulation
      • 8.3.3.2.3. By Therapeutic Area
  • 8.3.4. South Korea Formulation Development Outsourcing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Formulation
      • 8.3.4.2.3. By Therapeutic Area
  • 8.3.5. Australia Formulation Development Outsourcing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Formulation
      • 8.3.5.2.3. By Therapeutic Area

9. South America Formulation Development Outsourcing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service (Preformulation, Formulation Development)
  • 9.2.2. By Formulation (Oral, Injectable, Topical, Others)
  • 9.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Formulation Development Outsourcing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Formulation
      • 9.3.1.2.3. By Therapeutic Area
  • 9.3.2. Argentina Formulation Development Outsourcing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Formulation
      • 9.3.2.2.3. By Therapeutic Area
  • 9.3.3. Colombia Formulation Development Outsourcing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Formulation
      • 9.3.3.2.3. By Therapeutic Area

10. Middle East and Africa Formulation Development Outsourcing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service (Preformulation, Formulation Development)
  • 10.2.2. By Formulation (Oral, Injectable, Topical, Others)
  • 10.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Formulation Development Outsourcing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Formulation
      • 10.3.1.2.3. By Therapeutic Area
  • 10.3.2. Saudi Arabia Formulation Development Outsourcing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Formulation
      • 10.3.2.2.3. By Therapeutic Area
  • 10.3.3. UAE Formulation Development Outsourcing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Formulation
      • 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Formulation Development Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1 Charles River Laboratories.
  • 15.6.2 Aizant Drug Research Solutions Private Limited.
  • 15.6.3 Catalent Inc.
  • 15.6.4 Laboratory Corporation of America Holdings.
  • 15.6.5 Syngene International Ltd.
  • 15.6.6 Irisys LLC.
  • 15.6.7 Intertek Group PLC.
  • 15.6.8 Piramal Pharma Solutions.
  • 15.6.9 Qiotient Sciences Ltd.
  • 15.6.10 Patheon Inc.
  • 15.6.11 Emergent BioSolutions Inc
  • 15.6.12 Lonza Group AG

16. Strategic Recommendations